You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
康緣藥業(600557.SH):上半年淨利降40.46%至1.44億元
格隆匯 08-19 15:41

格隆匯 8 月 19日丨康緣藥業(600557.SH)披露2020年半年度報告,實現營業收入15.47億元,同比下降31.62%;歸屬於上市公司股東的淨利潤1.44億元,同比下降40.46%;歸屬於上市公司股東的扣除非經常性損益的淨利潤1.74億元,同比下降26.42%;基本每股收益0.24元。

報告期內,雖受疫情隔離措施等因素影響,公司抗感染系列用藥如熱毒寧注射液、金振口服液等藥品銷售收入下降幅度較大,但骨科產品複方南星止痛膏、腰痺通膠囊有較好的增長。同時,參烏益腎片在2019年新進醫保之前基本無銷售的情況下,2020年上半年銷售收入過千萬。2019年銀杏二萜內酯葡胺注射液經第二次談判後再次納入國家醫保目錄,醫保降價雖對該品種銷售額和公司上半年營業收入產生了一定的負面影響,但該品種在疫情環境下的銷售數量取得了較好的增長,以量換價效應明顯,未來發展可期。

2020年下半年,公司將持續推進營銷改革,加強市場推廣,發揮公司眾多獨家品種和醫保品種優勢,保證公司的穩定健康發展。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account